Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 (patentes nacionales, patentes europeas, informes tecnológicos de patentes y búsquedas retrospectivas) se encuentra cerrado desde el 19 de junio. La solicitud de ayudas para los Bonos 1, 2 y 4 permanecen abiertos.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
130
resultados
Última actualización
14/08/2025 [06:57:00]
Resultados 75 a 100 de 130
Resumen de: US2025213785A1
Disclosed herein are improved infusion sets that incorporate halogenated siloxane materials within the composition of an infusion set septum. Such configurations maintain the mechanical robustness of using elastomeric materials for a fluidic septum while providing barrier properties that prevent phenolic preservative from being absorbed out of the infusion set. Infusion sets as disclosed herein are particularly suitable for maintaining insulin's anti-microbial effectiveness over extended wear (e.g., 7 days) to maintain performance of the infusion set during extended wear and reduce the risk of insulin aggregate propagation.
Resumen de: US2025213784A1
Systems and methods are provided for enabling and disabling insulin pumps in a multi-pump insulin pump system. For example, multiple pumps (e.g., patch pumps) may be rotated to deliver insulin to a user. In one example, one patch pump may be worn while another patch pump is charging. Once the battery of the patch pump worn by the user is depleted, a mobile device may cause the enabled pump in operation and worn by the user to send the latest pump settings and configuration data to the mobile device which will share the information with the disabled pump. The disabled pump will then update the pump settings based on this information and the mobile device may active the pump such that is now enabled for insulin delivery. The mobile device may also facilitate pairing between the patch pumps and a CGM device as they enabled for use and disabled.
Resumen de: US2025218600A1
Glucose forecasting systems and methods that include a minimally invasive scalp-worn behind-the-ear EEG device that includes first and second sensors. With an application on a personal device, analyzing the processed EEG signals with a trained forecasting model and forecasting future glucose levels, of the subject; causing the personal device to visually present on a display information that is indicative of the forecasted future glucose levels.
Resumen de: US2025218565A1
The present disclosure provides a technology capable of appropriately supporting improvement of an individual's lifestyle. The lifestyle improvement support system is provided with an acquisition device capable of acquiring from a target person at least their blood glucose level data, physical activity data, and dietary activity data, as well as a controlling device.
Resumen de: US2025218598A1
Methods and devices include predicting future glucose and engagement levels for a user by receiving the user's glucose levels collected by a continuous glucose monitoring (CGM) device over a time period, receiving engagement data associated with the user, wherein the engagement data are associated with the user's medication intake, diet, physical activity, laboratory results, and education activity, determining a first glycemia risk index (GRI) value, determining, using a machine learning model and responsive to the user's glucose levels and the engagement data collected over the time period, one or more predictions for future glucose levels for the user including a prediction that a future GRI value is greater than or less than the first GRI value, and determining, using the machine learning model and responsive to the user's engagement data collected over the time period, one or more predictions for future engagement levels.
Resumen de: WO2025145062A1
Disclosed herein are system, method, and computer program product embodiments for calculating accurate doses for medication using improved user interface features that may be implemented as part of an application operating within a continuous glucose monitoring system. The disclosed interface provides an improved user experience when a medication delivery device is disconnected or does not have the ability to query the requisite data.
Resumen de: WO2025141541A1
Systems and methods are provided for enabling and disabling insulin pumps in a multi- pump insulin pump system. For example, multiple pumps (e.g., patch pumps) may be rotated to deliver insulin to a user. In one example, one patch pump may be worn while another patch pump is charging. Once the battery of the patch pump worn by the user is depleted, a mobile device may cause the enabled pump in operation and worn by the user to send the latest pump settings and configuration data to the mobile device which will share the information with the disabled pump. The disabled pump will then update the pump settings based on this information and the mobile device may active the pump such that is now enabled for insulin delivery. The mobile device may also facilitate pairing between the patch pumps and a CGM device as they enabled for use and disabled.
Resumen de: WO2025140911A1
A method performed by a computer system for monitoring diabetes and comprising: a model explainability phase, comprising steps of: - collecting specific foot data from at least one sensor disposed at least within a shoe insole of a user, - collecting a plurality of trained machine learning models configured for decision-making in diabetes diagnosis based on a plurality of collected data, - based on the plurality of trained machine learning models, generating a plurality of specific machine learning models, said specific machine learning models being specified for decision-making in diabetes diagnosis based on the specific foot data, and a model reliability assessment phase, comprising steps of: - evaluating a reliability of each of the specific machine learning model based on neutrosophic sets and intuitionistic fuzzy sets, - based on the result of the evaluation step, selecting the optimized machine learning model for monitoring diabetes based on the specific foot data.
Resumen de: WO2025144547A1
A continuous analyte monitoring system includes analyte sensors configured to sense analytes such as lactate and glucose in the tissue of a user. A controller is coupled to the analyte sensors and configured evaluate first samples of outputs of a first analyte sensor and second samples of outputs of a second analyte sensor to determine whether the first samples and the second samples indicate compression of the tissue. The controller compensates for the compression of the tissue with respect to the first samples. A force sensor may be used and may be positioned between a circuit board and a housing, the circuit board supported by supports providing preloading of the force sensor. A force deflector may be used to direct loads away from tissue holding the analyte sensors. A housing may have a flexible lower surface to reduce loading of the tissue.
Resumen de: US2025213147A1
Methods and devices include automated coaching for management of glucose states by receiving a user's glucose levels using a continuous glucose monitoring (CGM) device, determining a time in range (TIR) value, determining a TIR state, receiving a glucose variability (GV) value, determining a GV state, determining a starting state based on the TIR state and the GV state, determining that the starting state corresponds to a non-ideal state, generating an optimized pathway to reach an ideal state based on one or more account vectors such as addressing self-management behavior including food, activity, and medication use. The optimized pathway may further be based on computer detection and classification of significant events of interest over time.
Resumen de: US2025213146A1
There is provided a glucose sensor system comprising: a transmitter (2) for containing a battery (212), the transmitter being for placement on top of patient skin; a transcutaneous connector (3) comprising at least one conductive path; and an implantable monolithic integrated circuit (I) for placement beneath the patient skin, wherein the implantable monolithic integrated circuit comprises a potentiostat and an electrochemical sensing element; wherein the potentiostat is electrically coupled to the transmitter (2) via the transcutaneous connector (3), and the electrochemical sensing element is configured to sense glucose concentration and generate an electrical signal representative of the glucose concentration, and wherein the potentiostat is electrically connected to the electrochemical sensing element.
Resumen de: AU2025204350A1
Peritoneal dialysis, such as automated peritoneal dialysis (“APD”) is provided with any one or more or all of the following sensing or feedback features: impedance sensing to detect peritonitis, temperature sensing to detect peritonitis, bio-MEMS sensing to detect peritonitis, and glucose control for diabetes patients, wherein each sensing or feedback feature analyzes patient effluent fluid or fluid dwelling within a patient’s peritoneal cavity. Peritoneal dialysis, such as automated peritoneal dialysis ("APD") is provided with any one or more or all of the following sensing or feedback features: impedance sensing to detect peritonitis, temperature sensing to detect peritonitis, bio-MEMS sensing to detect peritonitis, and glucose control for diabetes patients, wherein each sensing or feedback feature analyzes patient effluent fluid or fluid dwelling within a patient's peritoneal cavity. un u n e r i t o n e a l d i a l y s i s , s u c h a s a u t o m a t e d p e r i t o n e a l d i a l y s i s ( " " ) i s p r o v i d e d w i t h a n y o n e o r m o r e o r a l l o f t h e f o l l o w i n g s e n s i n g o r f e e d b a c k f e a t u r e s : i m p e d a n c e s e n s i n g t o d e t e c t p e r i t o n i t i s , t e m p e r a t u r e s e n s i n g t o d e t e c t p e r i t o n i t i s , b i o - s e n s i n g t o d e t e c t p e r i t o n i t i s , a n d g l u c o s e c o n t r o l f o r d i a b e t e s p a t i e n t s , w h e r e i n e a c h s e n s i n g o r f e e d b a
Resumen de: WO2025141628A1
This blood glucose level measurement device comprises: a sensor unit that measures the blood glucose level of a user; a communication unit that transmits, to the outside, data representing the blood glucose level measured by the sensor unit; a flexible, sheet-shaped battery that supplies power to the sensor unit and the communication unit; a flexible, plate-shaped circuit unit that controls the operation of the communication unit; and a mounting unit that is configured to be mounted on the body of the user. The peak current of the battery is 20 mA or more.
Resumen de: WO2025143904A2
Disclosed is an RF biosensing system using an RF sensor including a glucose-responsive hydrogel-based microneedle. The RF biosensing system measures a sensing signal with a VNA by detecting a sensing signal by using a reader antenna and a reader antenna sensing circuit through a readout coil on the basis of RF biosensing and wireless transmission, via EM coupling between a glucose-responsive hydrogel-based microneedle, which is provided below a flexible substrate so as to be minimally invasively applied in vivo to the skin surface (on-site) of epidermis/dermis/hypodermis of the skin or to skin/fat/muscle tissue, and an RF sensor, which is positioned over the flexible substrate and uses the difference in resonant frequencies within frequencies of 400 to 3,000 MHz, and performs biosensing such as detection of proteins, glucose, and fat in the skin, on the basis of changes in the capacitance of a sensing antenna circuit (LC resonator) of the RF sensor, shifts in resonant frequencies of the LC resonator, and changes in S-parameters.
Resumen de: WO2025145037A1
Disclosed herein are portable infusion pump systems that provide an ability to simultaneously track insulin on board from insulin deliveries from different sources and/or of different types. A user interface can be provided to enable the user to enter insulin delivered from a source other than the portable infusion pump. A simplified calculation for estimating IOB remaining from each insulin delivery enables such calculations to be carried out with the limited memory and processing capacity of the portable infusion pump.
Resumen de: WO2025140653A1
The present application discloses a measurement method, a system, and a related apparatus. The method is applied to a first electronic device, wherein the first electronic device comprises a first electrode set and a second electrode set; the distance between the first electrode set and the second electrode set is greater than a first distance; and under the condition that the first electrode set and the second electrode set are implanted into subcutaneous tissue, the method comprises: determining a first physiological parameter by means of the first electrode set; and determining an electrocardiogram signal by means of the first electrode set and the second electrode set. In this way, an electrocardiogram signal of a user can be acquired by the first electronic device anytime and anywhere, and any one or more of other physiological parameters (such as blood glucose, blood ketone, blood lactate, and uric acid) of the user can also be measured, thereby improving the health monitoring efficiency.
Resumen de: WO2025140661A1
A blood glucose management method, a user interface, and a related apparatus. The blood glucose management method comprises: on the basis of historical blood glucose levels of a user, determining a first mealtime; on the basis of one or more of a mealtime inputted by the user, and body movements and the heart rate of the user, determining a second mealtime; on the basis of the first mealtime and the second mealtime, determining a third mealtime; and assessing a blood glucose health status of the user by means of the third mealtime. Historical mealtimes of a user that are determined using multiple methods are combined to predict a mealtime of the user, so that an electronic device can more accurately assess a blood glucose situation of the user.
Resumen de: WO2025145056A1
Disclosed herein are apparatuses and methods that account for exercise in closed loop insulin delivery systems. The apparatuses and methods disclosed herein address exercise-induced glucose level increases by reducing the target IOB within the closed loop. By reducing the target IOB, the algorithm responds less aggressively to pre-exercise food, and does not build up the IOB that could potentially contribute to undesirably low glucose levels once the exercise also begins lowering glucose levels. Following exercise, because the user's body will not immediately transition to a pre-exercise state, the algorithm will gradually transition back to the initial target IOB.
Resumen de: WO2025145024A1
Disclosed herein are improved infusion sets that incorporate halogenated siloxane materials within the composition of an infusion set septum. Such configurations maintain the mechanical robustness of using elastomeric materials for a fluidic septum while providing barrier properties that prevent phenolic preservative from being absorbed out of the infusion set. Infusion sets as disclosed herein are particularly suitable for maintaining insulin's anti-microbial effectiveness over extended wear (e.g., 7 days) to maintain performance of the infusion set during extended wear and reduce the risk of insulin aggregate propagation.
Resumen de: US2019013091A1
User interfaces are needed to alert and inform a person suffering from diabetes or a healthcare provider of possible harmful changes in the patient's blood glucose level. An improved method is presented for issuing an alert regarding a glucose condition of a patient by a diabetes management system. For a given patient, their glucose condition is quantified and presented as a state on a display. Glucose conditions can also be prioritized for a plurality of patients and presented to a healthcare provider.
Resumen de: AU2023415787A1
The present invention provides a sensor applicator assembly for a blood glucose meter, comprising: an applicator; and a body attachment unit which is disposed in the applicator, and which is composed of a housing including an upper frame and a lower frame, wherein the lower frame has a recessed part formed along the entire circumferential section thereof.
Resumen de: US2025213191A1
A continuous analyte monitoring system includes analyte sensors configured to sense analytes such as lactate and glucose in the tissue of a user. A controller is coupled to the analyte sensors and configured evaluate first samples of outputs of a first analyte sensor and second samples of outputs of a second analyte sensor to determine whether the first samples and the second samples indicate compression of the tissue. The controller compensates for the compression of the tissue with respect to the first samples. A force sensor may be used and may be positioned between a circuit board and a housing, the circuit board supported by supports providing preloading of the force sensor. A force deflector may be used to direct loads away from tissue holding the analyte sensors. A housing may have a flexible lower surface to reduce loading of the tissue.
Resumen de: LU505951B1
A method performed by a computer system for monitoring diabetes and comprising: a model explainability phase, comprising steps of: - collecting specific foot data from at least one sensor disposed at least within a shoe insole of a user, - collecting a plurality of trained machine learning models configured for decision-making in diabetes diagnosis based on a plurality of collected data, - based on the plurality of trained machine learning models, generating a plurality of specific machine learning models, said specific machine learning models being specified for decision-making in diabetes diagnosis based on the specific foot data, and a model reliability assessment phase, comprising steps of: - evaluating a reliability of each of the specific machine learning model based on neutrosophic sets and intuitionistic fuzzy sets, - based on the result of the evaluation step, selecting the optimized machine learning model for monitoring diabetes based on the specific foot data.
Resumen de: AU2023401746A1
Techniques for performing application-layer security and communication over primary invitation channels arc disclosed. In certain embodiments, analyte data is obtained from an analyte sensor electrically coupled to a sensor electronics module of an analyte sensor system. A secret key is established with a display device over one or more primary invitation channels. The analyte data is encrypted using the secret key. The encrypted analyte data is broadcast over the one or more primary invitation channels.
Nº publicación: US2025210156A1 26/06/2025
Solicitante:
ABBOTT DIABETES CARE INC [US]
ABBOTT DIABETES CARE INC
Resumen de: US2025210156A1
Methods and system to provide glycemic control and therapy management based on monitored glucose data, and current and/or target HbA1C levels are provided.
BOPI
Sede Electrónica
